Format

Send to

Choose Destination
Vaccine. 2005 May 25;23(28):3687-96.

Multicomponent Lyme vaccine: three is not a crowd.

Author information

1
The Center for Extracellular Matrix Biology, Texas A&M University System Health Science Center, Albert B. Alkek Institute of Biosciences and Technology, 2121 W, Holcombe Blvd., Suite 603, Houston, TX 77030, USA. ebrown2@uh.edu

Abstract

Lyme disease is caused by the spirochete Borrelia burgdorferi and it is the most common vector-borne disease in the United States. Disseminated spirochetes can persist in various tissues and can result in a variety of different disease manifestations. Vaccination trials testing various lipoprotein candidates have yielded mixed results despite the generation of robust antibody titers. Data presented in this report demonstrate that a combination vaccine composed of DbpA, BBK32 and OspC is more effective than single or double component formulations and that the ratio of each component dramatically impacts vaccine efficacy when tested in protection experiments against Borrelia following needle inoculation.

PMID:
15882529
DOI:
10.1016/j.vaccine.2005.02.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center